Legend Biotech Corp (LEGN) stock
LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$15.25−0.85 (-5.28%)
Close on Nov 20, 2026Market cap $2.82BP/E –Yield –
Legend Biotech free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Legend Biotech's free cash flow for the twelve months ending Jun 30, 2026 was -$121.80M. For fiscal 2025 it was -$128.80M. The highest annual figure on record is $286.72M in fiscal 2018.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$128.80M | – |
| FY2024 | Dec 31, 2024 | -$158.10M | – |
| FY2023 | Dec 31, 2023 | -$413.40M | – |
| FY2022 | Dec 31, 2022 | -$222.21M | – |
| FY2021 | Dec 31, 2021 | -$240.66M | – |
| FY2020 | Dec 31, 2020 | -$249.26M | – |
| FY2019 | Dec 31, 2019 | -$109.84M | -138.3% |
| FY2018 | Dec 31, 2018 | $286.72M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$28.40M | – |
| Q1 FY2026 | Mar 31, 2026 | -$92.60M | – |
| Q4 FY2025 | Dec 31, 2025 | -$24.57M | – |
| Q3 FY2025 | Sep 30, 2025 | $23.77M | – |
| Q2 FY2025 | Jun 30, 2025 | -$22.40M | – |
| Q1 FY2025 | Mar 31, 2025 | -$105.60M | -1238.5% |
| Q4 FY2024 | Dec 31, 2024 | -$84.42M | – |
| Q3 FY2024 | Sep 30, 2024 | -$77.89M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.07M | – |
| Q1 FY2024 | Mar 31, 2024 | $9.28M | – |
| Q4 FY2023 | Dec 31, 2023 | -$100.03M | – |
| Q3 FY2023 | Sep 30, 2023 | -$66.23M | – |
| Q2 FY2023 | Jun 30, 2023 | -$103.66M | – |
| Q1 FY2023 | Mar 31, 2023 | -$143.49M | – |
| Q4 FY2022 | Dec 31, 2022 | -$56.30M | – |
| Q3 FY2022 | Sep 30, 2022 | -$74.69M | – |
See a number that looks wrong?